Nifurantin (Nitrofurantoin)

Nitrofurantoin is reduced inside bacterial cells to reactive intermediates that bind to ribosomal proteins and DNA. This interferes with bacterial enzyme systems and damages genetic material, inhibiting protein synthesis and replication. The result is a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations against common uropathogens.

The dosage of Nifurantin is determined by the prescribing clinician based on the patient’s condition, renal function, and local treatment guidelines. Healthcare professionals select the appropriate strength, frequency, and duration of therapy to achieve optimal efficacy while minimizing the risk of adverse effects.

Safety of nitrofurantoin in pregnancy has not been definitively established, and it is generally avoided during the first trimester and near term. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in breast milk. Use is only recommended when the potential benefit outweighs any potential risk.

To order Nifurantin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any temperature requirements), and assists with import documentation.

Nitrofurantoin offers a narrow spectrum of activity focused on common uropathogens and is less likely to promote resistance compared with broad‑spectrum agents such as fluoroquinolones. Unlike trimethoprim‑sulfamethoxazole, it retains activity against some resistant strains but requires adequate renal function for urinary excretion. Choice of therapy depends on local susceptibility patterns and patient-specific factors.

Nifurantin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight to maintain stability and potency.

Nifurantin is taken orally with a full glass of water, preferably with food or milk to reduce gastrointestinal irritation. The tablets should be swallowed whole and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare professional and complete the full course of therapy even if symptoms improve.

Serious adverse events associated with nitrofurantoin include pulmonary toxicity (such as interstitial pneumonitis or fibrosis), hepatic injury, severe cutaneous reactions (e.g., Stevens‑Johnson syndrome), and hemolytic anemia in individuals with glucose‑6‑phosphate dehydrogenase deficiency. Patients should seek immediate medical attention if they experience persistent cough, shortness of breath, jaundice, rash, or dark urine.

Nifurantin is contraindicated in patients with severe renal impairment (creatinine clearance < 60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofuran derivatives, and those with glucose‑6‑phosphate dehydrogenase deficiency due to the risk of hemolysis. Caution is also advised for individuals with a history of pulmonary or hepatic disease.